281 related articles for article (PubMed ID: 8033142)
1. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
[TBL] [Abstract][Full Text] [Related]
2. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
Wells A; Souto JC; Solava J; Kassis J; Bailey KJ; Turner T
Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP.
Limonta P; Dondi D; Moretti RM; Maggi R; Motta M
J Clin Endocrinol Metab; 1992 Jul; 75(1):207-12. PubMed ID: 1320049
[TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells.
Marelli MM; Moretti RM; Dondi D; Motta M; Limonta P
Endocrinology; 1999 Jan; 140(1):329-34. PubMed ID: 9886842
[TBL] [Abstract][Full Text] [Related]
5. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145.
Moretti RM; Marelli MM; Dondi D; Poletti A; Martini L; Motta M; Limonta P
J Clin Endocrinol Metab; 1996 Nov; 81(11):3930-7. PubMed ID: 8923840
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
8. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
Irmer G; Bürger C; Müller R; Ortmann O; Peter U; Kakar SS; Neill JD; Schulz KD; Emons G
Cancer Res; 1995 Feb; 55(4):817-22. PubMed ID: 7850795
[TBL] [Abstract][Full Text] [Related]
9. Effects of LHRH agonists on the growth of human prostatic tumor cells: "in vitro" and "in vivo" studies.
Montagnani Marelli M; Moretti RM; Dondi D; Limonta P; Motta M
Arch Ital Urol Androl; 1997 Sep; 69(4):257-63. PubMed ID: 9396187
[TBL] [Abstract][Full Text] [Related]
10. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway.
Limonta P; Moretti RM; Marelli MM; Dondi D; Parenti M; Motta M
Endocrinology; 1999 Nov; 140(11):5250-6. PubMed ID: 10537155
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.
Borri P; Coronnello M; Noci I; Pesciullesi A; Peri A; Caligiani R; Maggi M; Torricelli F; Scarselli G; Chieffi O; Mazzei T; Mini E
Gynecol Oncol; 1998 Dec; 71(3):396-403. PubMed ID: 9887238
[TBL] [Abstract][Full Text] [Related]
14. Autocrine stimulation by gonadotrophin-releasing hormone-like factors of human hormone-responsive prostate cancer cells in culture.
Qayum A; Scaletsky R; Waxman J
Prog Clin Biol Res; 1990; 357():121-8. PubMed ID: 2170991
[No Abstract] [Full Text] [Related]
15. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers.
Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
Clin Cancer Res; 2001 Aug; 7(8):2340-3. PubMed ID: 11489810
[TBL] [Abstract][Full Text] [Related]
16. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract][Full Text] [Related]
17. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
18. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice.
Dondi D; Moretti RM; Montagnani Marelli M; Pratesi G; Polizzi D; Milani M; Motta M; Limonta P
Int J Cancer; 1998 May; 76(4):506-11. PubMed ID: 9590126
[TBL] [Abstract][Full Text] [Related]
19. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.
Halmos G; Arencibia JM; Schally AV; Davis R; Bostwick DG
J Urol; 2000 Feb; 163(2):623-9. PubMed ID: 10647698
[TBL] [Abstract][Full Text] [Related]
20. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
